Picture of Summit Therapeutics logo

SMMT Summit Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeLarge CapHigh Flyer

Annual cashflow statement for Summit Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
January 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line9.9-52.7-88.6-78.8-615
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items9.032.4214.727.3540
Unusual Items
Other Non-Cash Items
Changes in Working Capital-54.90.619-0.0678.62-2.37
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-35.1-48.1-72.6-41.6-76.8
Capital Expenditures-0.164-0.421-0.306-0.624-0.128
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-0.1670-588
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-0.331-0.421-0.306-0.624-588
Financing Cash Flow Items-1.71-0.048-0.172-0.155-0.619
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities44.550.677.962086.5
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash6.752.585.37577-577